170 Views | 108 Downloads
Corresponding Author: Sonal Singh MD, MPH, University of Massachusetts Medical School 55 Lake Ave North, Worcester, MA 01655. sonal.singh@umassmemorial.org
All presenters had the opportunity to review the manuscript and provide comments.
The study authors acknowledge the contributions of Daniel E. Forman, MD, to the present manuscript.
The authors thank the following NIA and NHLBI staff for coordinating and participating in the workshop: Lawrence C. Fine, MD, NHLBI; Evan Hadley, MD, Sergei V. Romashkan MD, PhD, and Marcel Salive, MD, NIA.
We thank the following individuals whose presentations at the workshop, in addition to those of the coauthors, stimulated the development of this article: Lesley Curtis, PhD, Duke Clinical Research Institute; Michelle Oden, PhD, MS, Oregon State University; Eric D. Peterson, MD, Duke Clinical Research Institute; Paul M. Ridker, MD, Brigham and Women’s Hospital, Harvard School of Medicine; Janice B. Schwartz MD, University of California San Francisco; Mary Sano, PhD, Icahn School of Medicine; Paul D. Thompson, MD, Hartford HealthCare Heart & Vascular Institute
Dr. Singh reports giving expert testimony for plaintiffs’ attorneys in litigation involving a statin.
Dr. Go reports receiving a research grant through his institution from Sanofi.
Dr. Wenger reports research grants, contracts, trial steering committee, trial data safety and monitoring board involvement with Gilead Sciences, NHLBI, Pfizer, and Society for Women’s Health Research. She also reports consultancies with Amgen, AstraZeneca, Gilead Sciences, Janssen Pharmaceuticals, and Merck.
Dr. Zoungas reports past participation in advisory boards, educational meetings or research on behalf of Monash University (for work unrelated to this paper) with AstraZeneca Pty Ltd, Eli Lilly Australia Pty Ltd, Merck Sharp & Dohme (Australia) Pty Ltd, and Novo Nordisk Pty Ltd.
Dr. Gurwitz serves as a member of the UnitedHealthcare Pharmacy and Therapeutics Committee.
The National Institute on Aging (NIA) funded the “Opportunities for Trials on Effects of Statins in Primary Prevention in Older Adults” workshop, which was held in Bethesda, Maryland, July 31-August 1, 2017, with support and participation from representatives of the National Heart, Lung, and Blood Institute (NHLBI).
Funding for this work was also supported by R24AG045050 from the NIA (JG, SF, AG).
© 2018, Copyright the Authors Journal compilation © 2018, The American Geriatrics Society